Creative Medical Technology Holdings Inc. (CELZ) carries a Roarable Rating of E (Strong Sell) with 20/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Creative Medical Technology Holdings Inc. (NASDAQ: CELZ) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 20/100 at a spot price of $0.62 (-4.81% 1D, market cap $5.0M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 3/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, CELZ ranks #987 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CELZ carries a Roarable E (20/100 RQD), trailing P/E of N/A, gross margin of 63.4%, and ROIC of -35.0%. By comparison, BTTC (Black Titan Corporation) holds a D- grade (38/100 RQD, P/E N/A, ROIC —, cap $4.8M) and CRIS (Curis Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $4.0M). Among the 5-stock peer group, CELZ leads on earnings multiple (N/A) while PMCB leads on capital efficiency (-30.2% ROIC).
Per CELZ's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001187953), Creative Medical Technology Holdings Inc. generated $6.0K in revenue (-45.5% YoY), -$6.0M in net income, and -$5.9M in free cash flow against $7.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 34.6 (NEUTRAL RANGE)
20D Institutional Volume Accumulation (±12.5% realized swing band)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While CELZ currently carries a cautious 20/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.91) and Max Pain ($0.65) forces dealer call-delta covering toward $4.96.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Creative Medical Technology Holdings Inc. (CELZ) dropped -4.81% to $0.62, trading at 2% of its 52-week range ($0.62 – $4.72). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
StockInvest.us report covering Creative Medical Technology Holdings Inc. (CELZ) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Creative Medical Technology Holdings Inc. (CELZ) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Creative Medical Technology Holdings Inc. (CELZ) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Creative Medical Technology Holdings Inc. (CELZ) market action, institutional positioning, and fundamental catalysts.
Quiver Quantitative report covering Creative Medical Technology Holdings Inc. (CELZ) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Creative Medical Technology Holdings Inc. (CELZ) market action, institutional positioning, and fundamental catalysts.
Investing.com Canada report covering Creative Medical Technology Holdings Inc. (CELZ) market action, institutional positioning, and fundamental catalysts.
Traders Union report covering Creative Medical Technology Holdings Inc. (CELZ) market action, institutional positioning, and fundamental catalysts.
International Scientific Presentation Underscores Encouraging Clinical Outcomes and Additional Biological Potency Findings Supporting Cell-Free Regenerative PlatformPHOENIX, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Creative Med
Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company advancing regenerative medicine technologies, today highlighted
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -45.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CELZ today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for CELZ. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Creative Medical Technology Holdings Inc. (CELZ) ranks #987 by composite RQD confidence (20/100, grade E) and #943 by equity capitalization ($5.0M). Within this direct 5-issuer industry benchmark cohort, CELZ leads on earnings valuation at N/A trailing P/E, while PMCB leads on capital efficiency and profitability with -30.2% ROIC and — gross margin. BTTC currently holds the highest overall quantitative score in the immediate peer group at 38/100 (D-) compared with CELZ at 20/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CELZ
ACTIVE
Creative Medical Technology Holdings Inc. | E | 20/100 | — | 63.4% | -35.0% | -4.81% | $5.0M | Benchmark Subject |
| BTTC Black Titan Corporation | D- | 38/100 | — | — | — | -3.17% | $4.8M | /bttc-vs-celz → |
| CRIS Curis Inc. | E | 27/100 | — | — | -35.0% | +10.17% | $4.0M | /cris-vs-celz → |
| LIMN Liminatus Pharma Inc. (Class A) | D- | 35/100 | — | — | -35.0% | -10.64% | $3.8M | /limn-vs-celz → |
| PMCB PharmaCyte Biotech Inc. | E | 34/100 | — | — | -30.2% | +2.71% | $3.2M | /pmcb-vs-celz → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Creative Medical Technology Holdings Inc. (CELZ) reported GAAP revenue of $6.0K (-45.5% vs. FY2024 revenue of $11.0K , and -33.3% cumulative change since FY2023) , GAAP net income of -$6.0M, operating cash flow of -$5.9M, and free cash flow of -$5.9M (-10.5% YoY). On the balance sheet, CELZ closed FY2025 with $7.8M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $6.0K | -$6.0M | -$5.9M | -$5.9M | $7.8M | — |
| FY2024 (FY) | 2024-12-31 | $11.0K | -$5.5M | -$5.3M | -$5.3M | $6.7M | — |
| FY2023 (FY) | 2023-12-31 | $9.0K | -$5.3M | -$8.0M | -$8.0M | — | — |
As of 2026-11-03, Creative Medical Technology Holdings Inc. (NASDAQ: CELZ) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 20/100 at a spot price of $0.62 (-4.81% 1D, market cap $5.0M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 3/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, CELZ ranks #987 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CELZ carries a Roarable E (20/100 RQD), trailing P/E of N/A, gross margin of 63.4%, and ROIC of -35.0%. By comparison, BTTC (Black Titan Corporation) holds a D- grade (38/100 RQD, P/E N/A, ROIC —, cap $4.8M) and CRIS (Curis Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $4.0M). Among the 5-stock peer group, CELZ leads on earnings multiple (N/A) while PMCB leads on capital efficiency (-30.2% ROIC).
Per CELZ's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001187953), Creative Medical Technology Holdings Inc. generated $6.0K in revenue (-45.5% YoY), -$6.0M in net income, and -$5.9M in free cash flow against $7.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
CELZ last traded at $0.62 (-4.81% on volume of 224,683 shares), positioning the stock -31.87% below its 50-day simple moving average ($0.91) and -60.26% below its 200-day simple moving average ($1.56). Across its 52-week range of $0.62 to $4.72, CELZ sits at the 0.0% percentile with a 14-day RSI of 34.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.70).
Creative Medical Technology Holdings Inc. (CELZ) earns a live Roarable RQD composite score of 20/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.62 (-4.81% 1D, market capitalization $5.0M).
Creative Medical Technology Holdings Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry..0B as reported in that section. — describes its specific products, customers, or revenue model beyond the sector and industry classification. Revenue is reported as — across the displayed financial periods.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Creative Medical Technology Holdings Inc. (CELZ) reported $6.0K in annual revenue (up from $11.0K in FY2024, -45.5% YoY) and -$6.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($9.0K revenue, -$5.3M net income) through FY2025, CELZ scaled operating cash flow to -$5.9M and free cash flow to -$5.9M, backed by $7.8M in total assets against $0 in total debt.
— for upstream suppliers, downstream customers, or sector correlations beyond the Health Care sector and Biotechnology: Biological Products industry classification. An investor should watch whether any future clinical or regulatory developments create dependencies that the current graph does not capture, and whether the Health Care sector and biological products industry trends affect the stock through the Macro Regime Fit pillar's noted sector sensitivity.
Real-time company headlines, analyst actions, and sector developments for Creative Medical Technology Holdings Inc. (CELZ) • Click "Debate This Headline" to argue it in the Roar Pit below
StockInvest.us report covering Creative Medical Technology Holdings Inc. (CELZ) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Creative Medical Technology Holdings Inc. (CELZ) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Creative Medical Technology Holdings Inc. (CELZ) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Creative Medical Technology Holdings Inc. (CELZ) market action, institutional positioning, and fundamental catalysts.
Quiver Quantitative report covering Creative Medical Technology Holdings Inc. (CELZ) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Creative Medical Technology Holdings Inc. (CELZ) market action, institutional positioning, and fundamental catalysts.
Investing.com Canada report covering Creative Medical Technology Holdings Inc. (CELZ) market action, institutional positioning, and fundamental catalysts.
Traders Union report covering Creative Medical Technology Holdings Inc. (CELZ) market action, institutional positioning, and fundamental catalysts.
Don't sleep on CELZ's setup in Health Care. Positive Ultrasome™ pilot data in a 30-person knee osteoarthritis study showed average knee pain scores falling about 65% over six months.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (20/100) backs up the fundamental quality.
@CreditSpread_Watch Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Biological Products (No Diagnostic Substances). If gross margin (63.4%) holds, EPS grows into the multiple faster than bears think.
Fading this rally in CELZ at $0.66. With an Altman Z of 0.2, a Piotroski F of 3/9, and ROIC of -35% against zero reported revenue, the forensic profile signals elevated distress risk.. With a beta of 1.0 and the stock sitting at $0.66 (52-wk range $0.62–$4.72), the easy multiple expansion is already priced in.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).